Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.

Article  CAS  PubMed  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.

Article  PubMed  PubMed Central  Google Scholar 

Huang K-l, Mashl RJ, Wu Y, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355–370.e314.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li P, Brown S, Williams M, et al. The genetic landscape of germlineDDX41variants predisposing to myeloid neoplasms. Blood. 2022;140(7):716–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin ES, Ferrer A, Mangaonkar AA, et al. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol. 2021;96(11):1450–60.

Article  CAS  PubMed  Google Scholar 

Mangaonkar AA, Patnaik MM. Hereditary predisposition to hematopoietic neoplasms. Mayo Clin Proc. 2020;95(7):1482–98.

Article  CAS  PubMed  Google Scholar 

Mangaonkar AA, Ferrer A, Pinto e Vairo F et al. Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clinic Proceedings. 2019;94(9):1753–1768.

Negoro E, Radivoyevitch T, Polprasert C, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30(12):2405–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abou Dalle I, Kantarjian H, Bannon SA, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2019;95(2):227–9.

Article  PubMed  Google Scholar 

Quesada AE, Routbort MJ, DiNardo CD, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019;94(7):757–66.

Article  CAS  PubMed  Google Scholar 

Sébert M, Passet M, Raimbault A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 2019;134(17):1441–4.

Article  PubMed  Google Scholar 

Qu S, Li B, Qin T, et al. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations. Br J Haematol. 2020;192(6):1006–10.

Article  PubMed  PubMed Central  Google Scholar 

Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baranwal A, Nanaa A, Viswanatha D, et al. Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia. Bone Marrow Transplant. 2022;57(11):1716–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bataller A, Loghavi S, Gerstein Y, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023;98(11):1780–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badar T, Nanaa A, Foran JM, et al. Clinical and molecular correlates of somatic and germline < i>DDX41 variants in patients and families with myeloid neoplasms. Haematologica. 2023;108(11):3033–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kusne Y, Badar T, Lasho T, et al. Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. Br J Haematol. 2025;206(4):1109–20.

Article  PubMed  PubMed Central  Google Scholar 

Toumeh N, Jabban Y, Nanaa A, et al. Clinical outcome and molecular profile in patients with DDX41 mutation hot-spots. Hematol Rep. 2025. https://doi.org/10.3390/hematolrep17030026.

Article  PubMed  PubMed Central  Google Scholar 

Korotev SC, Cheng JX, Haribabu Y et al. Overall cancer risk in people with deleterious germline < i>DDX41 variants. Haematologica. 2025.

Winstone L, Jung Y, Wu Y. DDX41: exploring the roles of a versatile helicase. Biochem Soc Trans. 2024;52(1):395–405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chlon TM, Patnaik MM. Germline DDX41 mutant predisposition syndromes: slow driver states to hematological malignancies. Am J Hematol. 2023;98(11):1673–6.

Article  CAS  PubMed  Google Scholar 

Miao L, Wang X, Yao M, Tao Y, Han Y. Clinicopathological and prognostic significance of DDX41 mutation in myeloid neoplasms: a systematic review and meta-analysis. Ann Hematol. 2025;104(5):2581–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shinriki S, Hirayama M, Nagamachi A, et al. DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells. Leukemia. 2022;36(11):2605–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma J, Mahmud N, Bosland MC, Ross SR. DDX41 is needed for pre- and postnatal hematopoietic stem cell differentiation in mice. Stem Cell Rep. 2022;17(4):879–93.

Article  CAS  Google Scholar 

Polprasert C, Schulze I, Sekeres Mikkael A, et al. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. Cancer Cell. 2015;27(5):658–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makishima H, Bowman TV, Godley LA. DDX41-associated susceptibility to myeloid neoplasms. Blood. 2023;141(13):1544–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim K, Ong F, Sasaki K. Current understanding of DDX41 mutations in myeloid neoplasms. Cancers. 2023. https://doi.org/10.3390/cancers15020344.

Article  PubMed  PubMed Central  Google Scholar 

Alkhateeb HB, Nanaa A, Viswanatha D, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022;6(2):528–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maierhofer A, Mehta N, Chisholm RA, et al. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing. Blood Adv. 2023;7(23):7346–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maciejewski JP, Padgett RA, Brown AL, Müller-Tidow C. DDX41-related myeloid neoplasia. Semin Hematol. 2017;54(2):94–7.

Article  PubMed  PubMed Central